CARVANA Insider Sales: 15,000-Share Form 144 Notice Filed
Rhea-AI Filing Summary
Form 144 filed for CARVANA CO. (CVNA) shows a proposed sale of 15,000 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE with an aggregate market value of $5,658,600.00. The filing lists prior acquisitions: 528 shares from restricted and performance stock units acquired 01/01/2023 and 14,472 shares from exercise of stock options dated 10/01/2025. The record of sales in the past three months shows four transactions by Paul Breaux totaling 63,000 shares on 08/01/2025, 08/04/2025, 08/05/2025 and 09/09/2025 with gross proceeds reported for each sale. The filer certifies they do not possess undisclosed material adverse information and references Rule 10b5-1 activity where indicated.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider sales continuing over several months; current notice covers a 15,000-share proposed sale via a broker.
The filing documents ongoing disposition activity by an individual associated with the issuer, including four prior sales in the past three months totaling 63,000 shares and a new proposed sale of 15,000 shares executed through Morgan Stanley Smith Barney LLC. Acquisition entries indicate both restricted/performance stock units and option exercises as the source of the shares to be sold. The filer affirms no undisclosed material information and notes Rule 10b5-1 sales where listed. For investors, this is a disclosure of insider liquidity events rather than operational or financial performance data.
TL;DR: The notice is a routine insider sale filing with a 10b5-1 reference and a standard representation about material nonpublic information.
The form includes a certification that the signer lacks material nonpublic information and indicates at least one sale designated as a 10b5-1 plan. The mix of RSUs and option exercises as sources of shares is disclosed, and sales have been executed through an institutional broker. This filing is primarily a governance and disclosure matter showing compliance with Rule 144 reporting requirements and, where applicable, Rule 10b5-1 procedures rather than signaling corporate governance changes.